Current diagnosis and treatment of visceral leishmaniasis

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 8, 2010, Pages 919-944

  Mondal, Smriti ^a   Bhattacharya, Pradyot ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

anti leishmanial therapy; combination therapy; liposomal amphotericin B; miltefosine; rK39 strip test; visceral leishmaniasis diagnosis

Indexed keywords

ALBENDAZOLE; AMLODIPINE; AMPHOMUL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DERIVATIVE; AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN B LIPID EMULSION; ANTIMONY DERIVATIVE; ANTIMONY GLUCONATE; BUPARVAQUONE; IRON; LACIDIPINE; LEISHMANIA POLYPROTEIN; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTAVALENT ANTIMONIAL; PHOSPHORYL LIPID A; POLYPROTEIN; RETINOL; SERTRALINE; SITAMAQUINE; SQUALENE; STIBOGLUCONATE SODIUM; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA STIBAMATE; ZINC;

ACUTE PANCREATITIS; AFRICA; AGGLUTINATION TEST; ANTIBODY DETECTION; ANTIGEN DETECTION; BONE MARROW BIOPSY; CHILL; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; FEVER; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; HYPOKALEMIA; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; INFECTION CONTROL; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; LATEX AGGLUTINATION TEST; LEISHMANIASIS; LIVER TOXICITY; LOW DRUG DOSE; MIXED INFECTION; MONOTHERAPY; NEPHROTOXICITY; OTOTOXICITY; PARASITE EXAMINATION; POLYMERASE CHAIN REACTION; PREVALENCE; RELAPSE; REVIEW; SEROLOGY; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; SOUTH AMERICA; SOUTH ASIA; SPLEEN BIOPSY; TERATOGENICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VECTOR CONTROL; VIRUS RESISTANCE; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIGENS, PROTOZOAN; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS;

EID: 77955584094     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.78     Document Type: Review

References (179)

1. Joshi A, Narain JP, Prasittisuk C et al. Can visceral leishmaniasis be eliminated from Asia? J. Vector Borne Dis. 45(2), 105-111 (2008).
2. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl. Trop. Dis. 2(10), e313 (2008).
3. Romero GA, Boelaert M. Control of visceral leishmaniasis in latin America - a systematic review. PLoS Negl. Trop. Dis. 4(1), e584 (2010).
4. den Boer M, Davidson RN. Treatment options for visceral leishmaniasis. Expert Rev. Anti Infect. Ther. 4(2), 187-197 (2006).
5. Lukes J, Mauricio IL, Schönian G et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl Acad. Sci. USA 104(22), 9375-9380 (2007).
6. Maurício IL, Stothard JR, Miles MA. The strange case of Leishmania chagasi. Parasitol. Today 16(5), 188-189 (2000).
7. Khalil EA, Zijlstra EE, Kager PA, El Hassan AM. Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop. Med. Int. Health 7, 35-44 (2002).
8. Kafetzis DA. An overview of paediatric leishmaniasis. J. Postgrad. Med. 49(1), 31-38 (2003).
9. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 3(2), 87-98 (2003).
10. Alvar J, Aparicio P, Aseffa A et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 21(2), 334-359 (2008).
11. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin. Diagn. Lab. Immunol. 9, 951-958 (2002).
12. Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop. Med. Int. Health 8, 733-739 (2003).
13. Bentwich Z. Concurrent infections that rise the HIV viral load. J. HIV Ther. 8, 72-75 (2003).
14. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Leishmaniasis in HIV infection. J. Postgrad. Med. 49, 39-49 (2003).
15. Fernandez Cotarelo MJ, Abellan Martinez J, Guerra Vales JM et al. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 37, 973-977 (2003).
16. Riera C, Fisa R, Lopez P et al. Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow up. Eur. J. Clin. Microbiol. Infect. Dis. 23, 899-904 (2004).
17. Deniau M, Canavate C, Faraut-Gambarelli F, Marty P. The biological diagnosis of leishmaniasis in HIV-infected patients. Ann. Trop. Med. Parasitol. 297(Suppl. 1), 115-133 (2003).
18. Delgado J, Macias J, Pineda JA et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am. J. Trop. Med. Hyg. 61, 766-769 (1999).
19. Ritmeijer K, Dejenie A, Assefa Y et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin. Infect. Dis. 43(3), 357-364 (2006).
20. Roberts MT. Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. Br. Med. Bull. 75-76, 115-130 (2006).
21. Singh S. New developments in diagnosis of leishmaniasis. Indian J. Med. Res. 123(3), 311-330 (2006).
22. da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am. J. Trop. Med. Hyg. 72(6), 811-814 (2005).
23. Abass EM, Mansour D, el Harith A. Demonstration of agglutinating anti Leishmania antibodies in lymph node aspirate for confirmation of kala-azar serodiagnosis. J. Med. Microbiol. 56(Pt 9), 1256-1258 (2007).
24. Reus M, García B, Vázquez V, Morales D, Fuster M, Sola J. Visceral leishmaniasis: diagnosis by ultrasound-guided fine needle aspiration of an axillary node. Br. J. Radiol. 78(926), 158-160 (2005).
25. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5(11), 873-882 (2007). (Pubitemid 47578388)
26. Sundar S, Singh RK, Bimal SK et al. Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a Phase III diagnostic accuracy study. Trop. Med. Int. Health 12(2), 284-289 (2007).
27. Iqbal J, Hira PR, Saroj G et al. Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J. Clin. Microbiol. 40(2), 475-479 (2002).
28. Cruz I, Chicharro C, Nieto J et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J. Clin. Microbiol. 44(7), 2343-2347 (2006).
29. Pedras MJ, de Gouva Viana L, de Oliveira EJ, Rabello A. Comparative evaluation of direct agglutination test, rK39 and soluble antigen ELISA and IFAT for the diagnosis of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 102(2), 172-178 (2008).
30. BenAbderrazzak S, Saghrouni F, Gaed- Meksi S et al. Immunochromatographic RK39 strip test in the serodiagnosis of visceral leishmaniasis in Tunisia. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
31. Chappuis F, Rijal S, Soto A, Menten J, Boelaert M. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. Br. Med. J. 333(7571), 723 (2006).
32. Boelaert M, El-Safi S, Hailu A et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans. R. Soc. Trop. Med. Hyg. 102(1), 32-40 (2008).
33. Mandal J, Khurana S, Dubey ML, Bhatia P, Varma N, Malla N. Evaluation of direct agglutination test, rk39 Test, and ELISA for the diagnosis of visceral leishmaniasis. Am. J. Trop. Med. Hyg. 79(1), 76-78 (2008).
34. Oliveira E, Pedras MJ, de Assis IE, Rabello A. Improvement of direct agglutination test (DAT) for laboratory diagnosis of visceral leishmaniasis in Brazil. Trans. R. Soc. Trop. Med. Hyg. 103(12), 1279-1281 (2009).
35. ter Horst R, Tefera T, Assefa G, Ebrahim AZ, Davidson RN, Ritmeijer K. Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am. J. Trop. Med. Hyg. 80(6), 929-934 (2009).
36. Terán-Angel G, Schallig H, Zerpa O, Rodríguez V, Ulrich M, Cabrera M. The direct agglutination test as an alternative method for the diagnosis of canine and human visceral leishmaniasis. Biomedica 27(3), 447-453 (2007).
37. Al-Nahhas SA, Al-Taweel AA, Al-Taweel MA. Assessment of the direct agglutination test, fast agglutination screening test, and rK39 dipstick test for the sero-diagnosis of visceral leishmaniasis in Syria. Saudi Med. J. 29(9), 1250-1254 (2008).
38. Mikaeili F, Fakhar M, Sarkari B, Motazedian MH, Hatam G. Comparison of serological methods (ELISA, DAT and IFA) for diagnosis of visceral leishmaniasis utilizing an endemic strain. Iran J. Immunol. 4(2), 116-121 (2007).
39. Jacquet D, Boelaert M, Seaman J et al. Comparative evaluation of freeze-dried and liquid antigens in the direct agglutination test for serodiagnosis of visceral leishmaniasis (ITMA-DAT/VL). Trop. Med. Int. Health 11(12), 1777-1784 (2006).
40. Hailu A, Schoone GJ, Diro E et al. Field evaluation of a fast anti-Leishmania antibody detection assay in Ethiopia. Trans. R. Soc. Trop. Med. Hyg. 100(1), 48-52 (2006).
41. Silva ES, Schoone GJ, Gontijo CM, Brazil RP, Pacheco RS, Schallig HD. Application of direct agglutination test (DAT) and fast agglutination screening test (FAST) for sero-diagnosis of visceral leishmaniasis in endemic area of Minas Gerais, Brazil. Kinetoplastid. Biol. Dis. 4, 4 (2005).
42. Islam MZ, Itoh M, Takagi H et al. Enzyme-linked immunosorbent assay to detect urinary antibody against recombinant rKRP42 antigen made from Leishmania donovani for the diagnosis of visceral leishmaniasis. Am. J. Trop. Med. Hyg. 79(4), 599-604 (2008).
43. Sarkari B, Hatam GR, Mikaeili F, Sadeghi H, Ebrahimi S. A comparative study of antigen and antibody detection in visceral leishmaniasis using serum and urine-based ELISA. Trop. Biomed. 25(2), 96-99 (2008).
44. Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, Ali N. Immune responses in kala-azar. Indian J. Med. Res. 123(3), 245-266 (2006).
45. Mansour D, Abass EM, El Mutasim M, Mahamoud A, El Harith A. Use of a newly developed beta-mercaptoethanol enzyme-linked immunosorbent assay to diagnose visceral leishmaniasis in patients in eastern Sudan. Clin. Vaccine Immunol. 14(12), 1592-1595 (2007).
46. Saha S, Mazumdar T, Anam K et al. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis. J. Clin. Microbiol. 43(3), 1269-1277 (2005).
47. Maalej IA, Chenik M, Louzir H et al. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. Am. J. Trop. Med. Hyg. 68(3), 312-320 (2003).
48. Mohapatra TM, Singh DP, Sen MR, Bharti K, Sundar S. Compararative evaluation of rK9, rK26 and rK39 antigens in the serodiagnosis of Indian visceral leishmaniasis. J. Infect. Dev. Ctries 4(2), 114-117 (2010).
49. Farajnia S, Darbani B, Babaei H, Alimohammadian MH, Mahboudi F, Gavgani AM. Development and evaluation of Leishmania infantum rK26 ELISA for serodiagnosis of visceral leishmaniasis in Iran. Parasitology 135(9), 1035-1041 (2008).
50. Romero HD, Silva Lde A, Silva-Vergara ML et al. Comparative study of serologic tests for the diagnosis of asymptomatic visceral leishmaniasis in an endemic area. Am. J. Trop. Med. Hyg. 81(1), 27-33 (2009).
51. Zijlstra EE, Nur Y, Desjeux P, Khalil EA, El-Hassan AM, Groen J. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop. Med. Int. Health 6(2), 108-113 (2001).
52. Ravindran R, Anam K, Bairagi BC et al. Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect. Immun. 72(2), 863-870 (2004).
53. Kumar D, Srividya G, Verma S et al. Presence of anti-Lepp12 antibody: a marker for diagnostic and prognostic evaluation of visceral leishmaniasis. Trans R. Soc. Trop. Med. Hyg. 102(2), 167-171 (2008).
54. Sakru N, Korkmaz M, Ozbel Y, Ertabaklar H, Sengul M, Toz SO. Investigation of asymptomatic visceral leishmaniasis cases using western blot in an endemic area in Turkey. New Microbiol. 30(1), 13-18 (2007).
55. de Souza Dias S, da Costa Pinheiro PH, Katz S, dos Santos MR, Barbiéri CL. A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi suitable for serodiagnosis of American visceral leishmaniasis. Am. J. Trop. Med. Hyg. 72(2), 126-132 (2005).
56. Sundar S, Maurya R, Singh RK et al. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J. Clin. Microbiol. 44(1), 251-253 (2006).
57. Monno R, Giannelli G, Rizzo C, De Vito D, Fumarola L. Recombinant K39 immunochromatographic test for diagnosis of human leishmaniasis. Future Microbiol. 4(2), 159-170 (2009).
58. Rouf MA, Rahman ME, Islam MN, Islam MN, Ferdous NN, Hossain MA. Sensitivity, specificity and predictive values of immunochromatographic strip test in diagnosis of childhood kala-azar. Mymensingh Med. J. 18(1 Suppl.), S1-S5 (2009).
59. Ritmeijer K, Melaku Y, Mueller M, Kipngetich S, Okeeffe C, Davidson RN. Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am. J. Trop. Med. Hyg. 74(1), 76-80 (2006).
60. Das ML, Deb M, Karki BM et al. Use of rK39 for diagnosis of post kala-azar dermal leishmaniasis in Nepal. Southeast Asian J. Trop. Med. Public Health 38(4), 619-625 (2007).
61. Salotra P, Sreenivas G, Ramesh V, Sundar S. A simple and sensitive test for field diagnosis of post kala-azar dermal leishmaniasis. Br. J. Dermatol. 145(4), 630-632 (2001).
62. Singh D, Pandey K, Das VN et al. Novel noninvasive method for diagnosis of visceral leishmaniasis by rK39 testing of sputum samples. J. Clin. Microbiol. 47(8), 2684-2685 (2009).
63. Veeken H, Ritmeijer K, Seaman J, Davidson R. Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan. Trop. Med. Int. Health 8(2), 164-167 (2003).
64. Chappuis F, Mueller Y, Nguimfack A et al. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J. Clin. Microbiol. 43(12), 5973-5977 (2005).
65. Deniau M, Cañavate C, Faraut-Gambarelli F, Marty P. The biological diagnosis of leishmaniasis in HIV-infected patients. Ann. Trop. Med. Parasitol. 97(Suppl. 1), 115-133 (2003).
66. Rabello A, de Assis TM, da Costa Braga A et al. Validation of the Rapid Test IT-LEISH for the diagnosis of human visceral leishmaniasis in Brazil. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
67. Canavate C, Flores M, Pradas MA, Gonzalez R, Nieto J, Singh S. Use of SIGNAL-KA kit for the diagnosis of visceral leishmaniasis in Spain. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
68. Singh S, Dey A, Sivakumar R. Applications of molecular methods for Leishmania control. Expert Rev. Mol. Diagn. 5(2), 251-265 (2005).
69. Diro E, Techane Y, Tefera T et al. Field evaluation of FD-DAT, rK39 dipstick and KATEX (urine latex agglutination) for diagnosis of visceral leishmaniasis in northwest Ethiopia. Trans. R. Soc. Trop. Med. Hyg. 101(9), 908-914 (2007).
70. Malaei S, Mohebali M, Akhoundi B, Zarei Z. Evaluation of latex agglutination test (Katex) for the detection of urinary antigens in human visceral leishmaniasis. J. Tehran Un. Med. Sci. 4, 101-108 (2006).
71. Hatam GR, Ghatee MA, Hossini SM, Sarkari B. Improvement of the newly developed latex agglutination test (Katex) for diagnosis of visceral leishmaniasis. J. Clin. Lab. Anal. 23(4), 202-205 (2009).
72. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J. Clin. Microbiol. 45(1), 21-25 (2007).
73. Prina E, Roux E, Mattei D, Milon G. Leishmania DNA is rapidly degraded following parasite death: an analysis by microscopy and real-time PCR. Microbes Infect. 9(11), 1307-1315 (2007).
74. Arora SK, Gupta S, Bhardwaj S, Sachdeva N, Sharma NL. An epitope-specific PCR test for diagnosis of Leishmania donovani infections. Trans. R. Soc. Trop. Med. Hyg. 102(1), 41-45 (2008).
75. Foulet F, Botterel F, Buffet P et al. Detection and identification of Leishmania species from clinical specimens by using a real-time PCR assay and sequencing of the cytochrome B gene. J. Clin. Microbiol. 45(7), 2110-2115 (2007).
76. Motazedian M, Fakhar M, Motazedian MH, Hatam G, Mikaeili F. A urine-based polymerase chain reaction method for the diagnosis of visceral leishmaniasis in immunocompetent patients. Diagn. Microbiol. Infect. Dis. 60(2), 151-154 (2008).
77. Vaish M, Babu YA, Mehrotra S et al. PCR based detection of Leishmania donovani in swab samples of visceral leishmaniasis: a non invasive diagnostic tool. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
78. Turki-Mannoubi L, Kbaier-Hachemi H, Barhoumi M, Chakroun AS, Guizani I. A variant of DDRT-PCR using anchored mini-exon primers for identification of differentially expressed sequences in Leishmania infantum. Arch. Inst. Pasteur Tunis. 85(1-4), 29-44 (2008).
79. De Doncker S, Hutse V, Abdellati S et al. A new PCR-ELISA for diagnosis of visceral leishmaniasis in blood of HIV-negative subjects. Trans. R. Soc. Trop. Med. Hyg. 99(1), 25-31 (2005).
80. Salam MA, Mondal D, Kabir M, Ekram AR, Haque R. PCR for diagnosis and assessment of cure in kala-azar patients in Bangladesh. Acta Trop. 113(1), 52-55 (2010).
81. Hochberg L, Rizvig F, Alan Magilla COL, Wagmana J, Gilmorea W. An overview of the Smart Leish real-time PCR diagnostic device. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
82. Suliman K, Nasereddin A, Ereqat S, Abdeen Z. Reverse dot blot (RDB)-PCR for the diagnosis of old world leishmaniasis. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
83. Mendez J, Brasov IE, Cortes E, Echazabal J, Weina PJ. Cellulose acetate electrophoresis (CAE) a vital technique in Leishmania diagnosis. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
84. Deborggraeve S, Laurent T, Espinosa D et al. A simplified and standardized polymerase chain reaction format for the diagnosis of leishmaniasis. J. Infect. Dis. 198(10), 1565-1572 (2008).
85. Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop. Med. Int. Health 5, 312-317 (2000).
86. Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin. Pharmacother. 6(16), 2821-2829 (2005).
87. Jha TK. Drug unresponsiveness and combination therapy for kala azar. Indian J. Med. Res. 123, 389-398 (2006).
88. Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31, 1104-1107 (2000).
89. Bern C, Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J. Med. Res. 123(3), 275-288 (2006).
90. Ritmeijer K, Davidson RN. Royal Society of Tropical Medicine and Hygiene joint meeting with Medecins Sans Frontieres at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Medecins sans frontieres interventions against kala-azar in the Sudan, 1989-2003. Trans R. Soc. Trop. Med. Hyg. 97(6), 609-613 (2003).
91. Das VN, Siddiqui NA, Pandey K et al. A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Ther. Clin. Risk Manag. 5(1), 117-124 (2009).
92. Khalil EA, el Hassan AM, Zijlstra EE et al. Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. Ann. Trop. Med. Parasitol. 92(2), 151-158 (1998).
93. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6(11), 849-854 (2001). Erratum in: Trop. Med. Int. Health 7(3), 293 (2002).
94. Das VN, Ranjan A, Sinha AN et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J. Assoc. Physicians India 49, 609-613 (2001).
95. den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M. Developments in the treatment of visceral leishmaniasis. Expert Opin. Emerg. Drugs 14(3), 395-410 (2009).
96. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect. Dis. 5(12), 763-774 (2005).
97. Thakur CP, Kumar A, Mitra G et al. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J. Med. Res. 128(1), 38-44 (2008).
98. Saha S, Mondal S, Ravindran R et al. IL-10- and TGF-b-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J. Immunol. 179(8), 5592-5603 (2007).
99. Mueller Y, Nguimfack A, Cavailler P et al. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann. Trop. Med. Parasitol. 102(1), 11-19 (2008).
100. Mueller Y, Mbulamberi DB, Odermatt P, Hoffmann A, Loutan L, Chappuis F. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop. Med. Int. Health 14(8), 910-917 (2009).
101. Singh RK, Pandey HP, Sundar S. Visceral leishmaniasis (kala-azar): challenges ahead. Indian J. Med. Res. 123(3), 331-344 (2006).
102. Agrawal S, Rai M, Sundar S. Management of visceral leishmaniasis: Indian perspective. J. Postgrad. Med. 51(Suppl. 1), S53-S57 (2005).
103. Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis. 43, 917-924 (2006).
104. Ritmeijer K, Ter Horst RCS, Davidson RN. Poor effectiveness of liposomal amphotericin-B (AmBisome) in HIV co-infected visceral leishmaniasia patients in Ethiopia. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
105. Lima N. Experience of Médecins Sans Frontires after 1 year of using liposomal amphotericin B (AmBisome) treatment for Indian visceral leishmaniasis under routine programme conditions in Bihar, India. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
106. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med. 362, 504 (2010).
107. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans. R. Soc. Trop. Med. Hyg. 101(1), 19-24 (2007).
108. Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann. Trop. Med. Parasitol. 99(6), 563-569 (2005).
109. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med. 362, 504 (2010).
110. Laguna F, Videla S, Jiménez-Mejías ME et al. Spanish HIV-Leishmania Study Group. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J. Antimicrob. Chemother. 52(3), 464-468 (2003).
111. López-Vélez R, Videla S, Márquez M et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J. Antimicrob. Chemother. 53(3), 540-543 (2004).
112. Dietze R, Milan EP, Berman JD et al. Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin. Infect. Dis. 17(6), 981-986 (1993).
113. Sundar S, Mehta H, Chhabra A et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin. Infect. Dis. 42(5), 608-613 (2006). (Pubitemid 43271372)
114. Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop. Med. Int. Health 13(9), 1208-1212 (2008).
115. Sundar S, Singh A, Agarwal D, Rai M, Agrawal N, Chakravarty J. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am. J. Trop. Med. Hyg. 80(5), 700-703 (2009).
116. Bodhe PV, Kotwani RN, Kirodian BG et al. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 93(3), 314-318 (1999).
117. Mondal S, Bhattacharya P, Rahaman M, Ali N, Goswami R. A curative immune profile one-week after treatment of Indian kala-azar patients predicts success with a short course liposomal amphotericin B therapy. PLoS Neglected Tropical Diseases (2010) (In Press).
118. Sundar S, Rosenkaimer F, Makharia MK et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352(9143), 1821-1823 (1998).
119. Sundar S, Olliaro P. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther. Clin. Risk Manag. 3(5), 733-740 (2007).
120. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347(22), 1739-1746 (2002).
121. Bhattacharya SK, Sinha PK, Sundar S et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis. 196(4), 591-598 (2007).
122. Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am. J. Trop. Med. Hyg. 80(4), 580-582 (2009).
123. Das VN, Pandey K, Verma N et al. Short report: development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Am. J. Trop. Med. Hyg. 80(3), 336-338 (2009).
124. Dorlo TP, van Thiel PP, Huitema AD et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob. Agents Chemother. 52(8), 2855-2860 (2008).
125. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 84, 221-225 (1990).
126. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med. 356, 2571-2581 (2007).
127. Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin. Infect. Dis. 49(6), 914-918 (2009).
128. Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin. Investig. Drugs 17, 787-794 (2008).
129. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J. Med. Res. 123(3), 345-352 (2006).
130. Dietze R, Carvalho SF, Valli LC et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg. 65, 685-689 (2001).
131. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis. 10(3), 184-194 (2010).
132. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 123(3), 399-410 (2006).
133. Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am. J. Trop. Med. Hyg. 77(1), 89-94 (2007).
134. Ramesh V, Kumar J, Kumar D, Salotra P. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis. Indian J. Dermatol. Venereol. Leprol. 76(2), 138-144 (2010).
135. Sundar S, Rai M, Chakravarty J et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis. 47(8), 1000-1006 (2008).
136. Lackovic K, Parisot JP, Sleebs N et al. Inhibitors of leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small molecule chemical library. Antimicrob. Agents Chemother. 54(5), 1712-1719 (2010).
137. Mondal D, Singh SP, Kumar N et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl. Trop. Dis. 3(1), e355 (2009).
138. Ostyn B, Vanlerberghe V, Picado A et al. Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop. Med. Int. Health 13(8), 1073-1085 (2008).
139. Croft SL. PKDL - a drug related phenomenon? Indian J. Med. Res. 128(1), 10-11 (2008).
140. Thakur CP, Kumar A, Mitra G et al. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J. Med. Res. 128(1), 38-44 (2008).
141. Davis AJ, Murray HW, Handman E. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol. 20(2), 73-76 (2004).
142. Smith AC, Yardley V, Rhodes J, Croft SL. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 44(6), 1494-1498 (2000).
143. Bern C, Courtenay O, Alvar J. Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination. PLoS Negl. Trop. Dis. 4(2), e599 (2010).
144. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 31(3), 174-177 (2003).
145. Santos MA, Marques RC, Farias CA et al. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis. Rev. Soc. Bras. Med. Trop. 35(6), 629-633 (2002).
146. Romero HD, Silva Lde A, Silva-Vergara ML et al. Comparative study of serologic tests for the diagnosis of asymptomatic visceral leishmaniasis in an endemic area. Am. J. Trop. Med. Hyg. 81(1), 27-33 (2009).
147. Mikaeili F, Fakhar M, Sarkari B, Motazedian MH, Hatam G. Comparison of serological methods (ELISA, DAT and IFA) for diagnosis of visceral leishmaniasis utilizing an endemic strain. Iran J. Immunol. 4(2), 116-121 (2007).
148. el Mutasim M, Mansour D, Abass EM, Hassan WM, el Harith A. Evaluation of a glycerol-preserved antigen in the direct agglutination test for diagnosis of visceral leishmaniasis at rural level in eastern Sudan. J. Med. Microbiol. 55(Pt 10), 1343-1347 (2006).
149. Sundar S, Singh RK, Maurya R et al. Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans. R. Soc. Trop. Med. Hyg. 100(6), 533-537 (2006).
150. Bimal S, Das VNR, Sinha PK et al. Usefulness of the direct agglutination test in the early detection of subclinical Leishmania donovani infection: a community-based study. Ann. Trop. Med. Parasitol. 99(8), 743-749 (2005).
151. Yeganeh F, Barkhordari F, Omidi M et al. Cloning and expression of Leishmania major superoxide dismutase B1: a potential target antigen for serodiagnosis of Leishmaniasis. Iran J. Immunol. 6(3), 130-140 (2009).
152. Viana LDG, de Assis TSM, Orsini M et al. Combined diagnostic methods identify a remarkable proportion of asymptomatic Leishmania (Leishmania) chagasi carriers who present modulated cytokine profiles. Trans. R. Soc. Trop. Med. Hyg. 102(6), 548-555 (2008).
153. Mansour D, Abass EM, Mahamoud A, el Harith A. Qualitative and semi-quantitative comparison of an rK39 strip test and direct agglutination test for detection of anti-Leishmania donovani antibodies in the Sudan. Iran J. Immunol. 6(4), 208-215 (2009).
154. Chappuis F, Rijal S, Jha UK et al. Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal. Trop. Med. Intl. Health. 2(1), 31-40 (2006).
155. Welch RJ, Anderson BL, Litwin CM. Rapid immunochromatographic strip test for detection of anti-K39 immunoglobulin G antibodies for diagnosis of visceral leishmaniasis. Clin. Vaccine Immunol. 15(9), 1483-1484 (2008).
156. Alam M, Shamsuzzaman A, Musa A et al. Antigen detection from urine of kala-azar cases by latex agglutination test. Mymensingh Med. J. 17(1), 22-27 (2008).
157. Fisa R, Riera C, López-Chejade P et al. Leishmania infantum DNA detection in urine from patients with visceral leishmaniasis and after treatment control. Am. J. Trop. Med. Hyg. 78(5), 741-744 (2008).
158. Brustoloni YM, Lima RB, da Cunha RV et al. Sensitivity and specificity of polymerase chain reaction in Giemsastained slides for diagnosis of visceral leishmaniasis in children. Mem. Inst. Oswaldo Cruz. 102(4), 497-500 (2007).
159. Aoun K, Chouihi E, Amri F, Mary C, Bouratbine A. Contribution of real-time PCR to the follow up of visceral leishmaniasis cases on treatment. Presented at: Worldleish4. Lucknow, India, 3-7 February 2009.
160. Alborzi A, Pourabbas B, Shahian F, Mardaneh J, Pouladfar GR, Ziyaeyan M. Detection of Leishmania infantum kinetoplast DNA in the whole blood of asymptomatic individuals by PCR-ELISA and comparison with other infection markers in endemic areas, southern Iran. Am. J. Trop. Med. Hyg. 79(6), 839-842 (2008).
161. Wasan KM, Wasan EK, Gershkovich P et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J. Infect. Dis. 200(3), 357-360 (2009).
162. Tekwani BL, Walker LA. 8-aminoquinolines: future role as antiprotozoal drugs. Curr. Opin. Infect. Dis. 19(6), 623-631 (2006).
163. Garnier T, Mäntylä A, Järvinen T, Lawrence J, Brown M, Croft S. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J. Antimicrob. Chemother. 60(4), 802-810 (2007).
164. Palit P, Ali N. Oral therapy with amlodipine and lacidipine, 1,4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 52(1), 374-377 (2008).
165. Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbiéri CL, Uliana SR. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J. Antimicrob. Chemother. 63(2), 365-368 (2009).
166. Misra P, Sashidhara KV, Singh SP et al. 16a-Hydroxycleroda-3,13 (14)Z-dien- 15,16-olide from Polyalthia longifolia: a safe and orally active antileishmanial agent. Br. J. Pharmacol. 159(5), 1143-1150 (2010).
167. Palit P, Ali N. Oral therapy with sertraline, a selective serotonin reuptake inhibitor, shows activity against Leishmania donovani. J. Antimicrob. Chemother. 61(5), 1120-1124 (2008).
168. Banerjee A, De M, Ali N. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J. Immunol. 181(2), 1386-1398 (2008).
169. Reichwald C, Shimony O, Dunkel U, Sacerdoti-Sierra N, Jaffe CL, Kunick C. 2-(3-aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype. J. Med. Chem. 51(3), 659-665 (2008).
170. Bakunov SA, Bakunova SM, Bridges AS et al. Synthesis and antiprotozoal properties of pentamidine congeners bearing the benzofuran motif. J. Med. Chem. 52(18), 5763-5767 (2009).
171. Visceral leishmaniasis. Global view www.dndi.org/diseases/vl/global-view. html
172. Kala-azar status in South East Asia Region www.searo.who.int/en/ Section10/ Section2163-11668.htm
173. Report of the Fifth Consultative meeting on Leishmania/HIV Coinfection http://who.int/leishmaniasis/resources/ Leishmaniasis-hiv-coinfection5.pdf
174. WHO (2005b) Report of a WHO informal Consultation on Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis. Rome, Italy, 16 April 2005 www.who.int/neglected-diseases/ resources/AmBisomeReport.pdf
175. VL Clinical Studies in East Africa www.dndi.org/newsletters/n18/3-2.php
176. Shorter, easier treatment shows promise in India. TDR News, No.84, December 2009 http://apps.who.int/tdr/svc/publications/tdrnews/issue-84/ research-briefs#shorter-easier
177. XE www.xe.com
178. Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS www.who.int/medicinedocs/en/d/ Js5414e/2.html
179. ClinicalTrials.gov http://clinicaltrials.gov/ct2/ results?term=kala-azar